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Stent implantation is the default strategy for percutaneous coronary intervention (PCI). 1 Acute recoil and residual dissections as well as late recoil, a major determinant of restenosis after balloon angioplasty, are prevented by stents. 2, 3 However, stenting induces vessel wall injury that promotes neointimal hyperplasia which is greater after bare metal stent (BMS) implantation than following balloon angioplasty. 2, 3 Nevertheless, the larger initial lumen gain and the elimination of acute and late recoil by BMS translates into a larger coronary lumen at follow-up and significantly reduced restenosis rates. 2, 3 However, in-stent restenosis (ISR) remains a major limitation of PCI. 4 The main underlying mechanism of ISR is neointimal proliferation, though neoatherosclerosis has also been implicated. 4 Drug-eluting stents (DES) were introduced with the aim of inhibiting neointimal hyperplasia, but ISR may still occur, especially when DES are implanted in adverse clinical and anatomic scenarios. 4 In addition, DES require prolonged dual antiplatelet therapy (DAPT). 5 Some patients are unable to adhere to prolonged DAPT regimens or have a high risk of bleeding. 5 Dual antiplatelet therapy is also a cause of concern in patients with atrial fibrillation (AF) or any other condition requiring chronic oral anticoagulation. 5 Finally, economic issues may limit the universal use of DES. These factors explain why a number of patients still receive a BMS.
Several clinical, angiographic, and procedure-related factors have been implicated in the pathogenesis of ISR. [6] [7] [8] [9] Among the clinical factors, diabetes emerges as the most important risk factor for aggressive neointimal proliferation. 8 Vessel size and lesion length represent key determinants for recurrent stenosis after stent implantation. [6] [7] [8] [9] Suboptimal stent implantation (mainly underexpansion) secondary to either a poor deployment technique or complex anatomy has been related to late stent failure. 4 However, predicting ISR risk in an individual patient remains a challenge. [6] [7] [8] [9] In a previous issue of Angiology, Yilmaz et al 10 assessed the potential of the CHA 2 DS 2 -VASc score to predict the occurrence of ISR after BMS implantation in patients free from AF. The CHA 2 DS 2 -VASc score assigns 1 point for congestive heart failure, hypertension, age 65 to 74 years, diabetes mellitus, vascular disease and female sex, and 2 points for age 75 years or older and previous stroke. 11 In this study, patients (n ¼ 1350) undergoing successful BMS implantation were retrospectively analyzed; 700 of these patients were included in the final analysis (age 61.4 + 9 years, 63% men). The mean time from initial stent implantation to late coronary angiography was 14.2 + 3.5 months. At late follow-up, 265 (38%) patients developed ISR. Those presenting with ISR more frequently had diabetes, hyperlipidemia, history of cerebrovascular events, or heart failure and were more frequently smokers. Left ventricular ejection fraction and stent diameter were also predictors of ISR. All patients in the study 10 had at least 1 point in the CHA 2 DS 2 -VASc score, as they all had evidence of vascular disease. The mean CHA 2 DS 2 -VASc score was significantly higher in the group developing ISR (3.7 + 1.8 vs 2.1 + 1.4; P < .001). A CHA 2 DS 2 -VASc score of 3 was predictive of ISR (sensitivity 82% and specificity 76%). Moreover, there was a significant positive correlation between CHA 2 DS 2 -VASc score and C-reactive protein levels. On multivariate logistic regression analysis, diabetes, hyperlipidemia, smoking, stent length, and the CHA 2 DS 2 -VASc score were independent predictors of ISR.
This study 10 is of clinical interest and suggests that the CHA 2 DS 2 -VASc risk score may be useful to predict the risk of ISR in patients undergoing BMS implantation. Discussing some methodological issues would be of value.
First, this is a retrospective analysis of patients treated with BMS over a 5-year period. Importantly, patients with AF or clinical evidence of major systemic diseases were excluded. Accordingly, patient population was relatively selected and only from a single center.
Second, the reason for selecting BMS in this patient cohort was not indicated. Third, all patients included in the present analysis had a late angiographic surveillance. It is unclear whether this was required for symptoms or whether it was mandated in some patients as part of the local protocols. The authors state that patients underwent control angiography as a result of symptoms or noninvasive detection of ischemia. This strategy is clinically adequate but suggests a potential selection bias as some patients may develop ISR but be completely asymptomatic.
Fourth, restenosis was defined as narrowing >50% in a stented segment compared with the normal vessel diameter by "visual" assessment. Nowadays, quantitative coronary angiography is considered as the gold standard to detect the presence of ISR. Although this remains a study limitation, the reported intraobserver and interobserver variability (95%) was highly reassuring. In spite of these caveats, Yilmaz et al 10 provide novel, hypothesis-generating information.
Previous Studies on the CHA 2 DS 2 -VASc Risk Score
Atrial fibrillation confers an excess risk of stroke, but this risk also depends on other risk factors. Most clinical practice guidelines recommend the CHA 2 DS 2 -VASc score for stroke risk stratification in patients with AF. The CHA 2 DS 2 -VASc score extends the older CHADS 2 score by the inclusion of additional stroke risk factors (aged 65-74, vascular disease, and female sex). 11 The CHA 2 DS 2 -VASc has now been extensively validated in numerous independent cohorts and seems to be predictive of stroke and mortality in AF and non-AF cohorts treated or not treated with oral anticoagulants.
All the individual components of this score are important prognostic factors for cardiovascular disease and they have shown a close association with major cardiovascular outcomes. Indeed, this "clinical" risk score has also been found to have a significant predictive value for adverse outcomes in a myriad of cardiovascular pathologies ( Table 1 ). The CHADS score could effectively predict the risk of ischemic stroke in coronary patients without AF. 28 Similarly, both CHADS 2 and CHA 2 DS 2 -VASc scores have been consistently associated with stroke risk in non-AF patients and in those with noncompaction cardiomyopathy. [12] [13] [14] [15] Notably these scores incorporate most of the classic risk factors for the development of coronary artery disease (excluding hyperlipidemia, smoking, and family history) and have shown to accurately predict the presence, severity, and extent of atherosclerotic coronary artery disease in several patient subsets. 16, 17 The CHA 2 DS 2 -VASc score has been able to predict adverse clinical outcomes in patients with both stable coronary artery disease and acute coronary syndromes, irrespective of the presence of AF. In addition, it may be of help for risk stratification in patients admitted for an acute myocardial infarction. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] This score has also been used to predict adverse events after coronary revascularization. Importantly, in patients with known coronary artery disease, higher CHADS scores have been linked to a poor prognosis and a higher rate of adverse clinical outcomes following PCI and bypass grafting surgery. [18] [19] [20] These scores have been used to predict the risk of contrast-induced nephropathy. 29 Higher CHADS 2 score has been associated with coronary microvascular dysfunction on magnetic resonance imaging. 21 Likewise, in patients without AF, the CHADS 2 score has a strong correlation with the presence of peripheral arterial disease. 22 A high CHADS 2 score predicts the risk of first-time AF appearance, the time to a first cardiovascular hospitalization and also the occurrence of major bleeding in patients with AF. 23 CHA 2 DS 2 -VASc shares some variables with another well known score, the "hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly patients [>65 years], drugs/alcohol concomitantly" (HAS-BLED) score , therefore, explaining its ability to also predict bleeding risks. 24, 25 Last but not least, the CHADS score has been shown to be linked to all cause and cardiovascular mortality in different settings, supporting the high predictive power of CHADS scales to predict cardiovascular disease in the general population, irrespective of the presence or absence of AF. [24] [25] [26] Interestingly, the CHA 2 DS 2 -VASc score has also been recently associated with the prognosis of patients undergoing transcatheter aortic valve implantation. 27 Therefore, the use of the CHADS scores in predicting ischemic stroke, thromboembolism, and death extends well beyond the originally proposed AF field. However, until now its value to predict the risk of ISR is unknown. Stroke or transient ischemic attack in patients without known AF. 13 Postoperative cardiac surgery strokes independent of the presence of AF.
14 Embolic risk in left ventricular hypertrabeculation. 15 Coronary artery disease Presence and severity of CAD in asymptomatic patients with stroke 16 Risk of severe CAD in symptomatic patients. 17 Outcomes after PCI in a high-risk AF population. Long-term predictor for prognosis in patients with acute myocardial infarction. 19 Long-term outcome after coronary artery bypass graft surgery. 20 Coronary microvascular dysfunction. 21 Various Incidence of peripheral arterial disease. 22 Risk of new onset AF. 23 First cardiovascular hospitalization in patients with AF. 24 Bleeding risk in patients with AF. 25 Clinical outcomes and mortality in HF patients with or without AF. 26 Mortality in patients undergoing TAVI.
27
Abbreviations: AF, atrial fibrillation; CAD, coronary artery disease; HF, heart failure; PCI, percutaneous coronary intervention; TAVI, transcatheter aortic valve implantation. a The CHA 2 DS 2 -VASc score assigns 1 point for congestive heart failure, hypertension, age 65 to 74 years, diabetes mellitus, vascular disease, and female sex and 2 points for age 75 years or older and previous stroke.
Concluding Remarks
Yilmaz et al 10 suggest that in patients without AF undergoing BMS implantation, the CHA 2 DS 2 -VASc score can predict the risk of ISR. This clinical score might help in the clinical decision-making process involved in the selection to implant a BMS. However, DES implantation is currently recommended for most patients undergoing coronary interventions. 5 Further studies are required to assess whether this widely used clinical risk score may also predict the risk of stent failure (either ISR or stent thrombosis) in patients treated with DES.
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